Scanning Medical Journals
No new significant updates or guidelines matching this topic were found today. We will check again soon.
MIPSS70+ v2.0: Mutation and Karyotype-enhanced IPSS for Primary Myelofibrosis. Essential for transplant timing in candidates ≤ 70 years.
Cytogenetic Risk Class
MIPSS70+ v2.0 Score
Risk Category
Estimated Median Survival: > 20 yr
Standard surveillance or targeted therapy (e.g. Ruxolitinib) transition based on symptoms.
Verified
Last Review: 2026
Last Comprehensive Review: 2026
